Matthew C. Hill - 05 Jan 2023 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Reporting relationship: Chief Financial Officer
Issuer ticker: PDSB
Reported as of: 05 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2023, 15:59:18 UTC
Prior SEC filing: 14 Dec 2021
Next SEC filing: 06 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Matthew C. Hill

Key filing fact

Matthew C. Hill filed Form 4 for PDS Biotechnology Corp (PDSB) on 06 Jan 2023.

Key facts

This page summarizes Matthew C. Hill's Form 4 filing for PDS Biotechnology Corp (PDSB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2023, 15:59.

Change

Previous filing in this sequence was filed on 14 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PDSB transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +161,200
Change %
Price: $0.000000
Shares after: 161,200
Date: 05 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 161,200
Exercise price: $11.61
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option, representing a right to purchase a total of 161,200 shares of Common Stock, will become exercisable on January 5, 2024, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 5, 2027.